Development and validation of a spectrofluorimetric method for the determination of erlotinib in spiked human plasma

Journal of Fluorescence

Volumn 22, Issue 6, 2012, Pages 1425-1429

  Mandal, Bivash ^a   Balabathula, Pavan ^a   Mittal, Nivesh ^a   Wood, George C ^a   Bhattacharjee, Himanshu ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Erlotinib; Spectrofluorimetric; Spiked human plasma; Validation

Indexed keywords

ANALYTICAL PARAMETERS; ANTICANCER DRUG; DERIVATIZATIONS; DETECTION LIMITS; ERLOTINIB; FLUORESCENCE INTENSITIES; LIMIT OF DETECTION; LIMIT OF QUANTIFICATIONS; LIQUID-LIQUID EXTRACTION; SPECTROFLUORIMETRIC; SPECTROFLUORIMETRIC METHODS; SPIKED HUMAN PLASMAS; VALIDATION;

PLASMAS;

PLASMA (HUMAN);

ANTINEOPLASTIC AGENT; ERLOTINIB; QUINAZOLINE DERIVATIVE;

ARTICLE; BLOOD; BLOOD ANALYSIS; CHEMISTRY; HUMAN; METHODOLOGY; SPECTROFLUOROMETRY; TIME; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; HUMANS; QUINAZOLINES; SPECTROMETRY, FLUORESCENCE; TIME FACTORS;

EID: 84869500605     PISSN: 10530509     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10895-012-1103-8     Document Type: Article

References (18)

1. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-59
2. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Eng J Med 364:947-955
3. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. New Eng J Med 358:1160-1174
4. Masters AR, Sweeney CJ, Jones DR (2007) The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B 848:379-383
5. Signor L, Varesio E, Staack RF, Starke V, Richter WF, Hopfgartner G (2007) Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. J Mass Spec 42:900-909
6. Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A (2003) Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B 796:181-188
7. Pujeri S, Khader A, Seetharamappa J (2009) Validated stabilityindicating chromatographic method for the assay of erlotinib active pharmaceutical ingredient. Anal Lett 42:1855-1867
8. Pan J, Jiang X, Chen YL (2010) Automatic supported liquid extraction (SLE) coupled with HILIC-MS/MS: an application to method development and validation of erlotinib in human plasma. Pharmaceutics 2:105-118
9. Aydoǧmuş Z, Sari F, Ulu ST (2011) Spectrofluorimetric Determination of Aliskiren in Tablets and Spiked Human Plasma through Derivatization with Dansyl Chloride. J Fluoresc (In press):1-8
10. Kepekci Tekkeli SE, Önal A (2011) Spectrofluorimetric Methods for the Determination of Gemifloxacin in Tablets and Spiked Plasma Samples. J Fluoresc (In press):1-7
11. El-Enany NM, El-Sherbiny DT, Abdelal AA, Belal FF (2010) Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde. J Fluoresc 20:463-472
12. Ulu ST (2009) Highly sensitive spectrofluorimetric determination of lomefloxacin in spiked human plasma, urine and pharmaceutical preparations. Eur J Med Chem 44:3402-3405
13. Rasoulzadeh F, Asgari D, Naseri A, Rashidi MR (2010) Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin. DARU 18:179-180
14. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y et al (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496
15. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH et al (2010) Pharmacokinetics of erlotinib and its active metabolite OSI- 420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol 5:601-605
16. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A et al (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46:282-90
17. Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S et al (2011) A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. J Chromatogr B 879:2345-50
18. Meany HJ, Fox E, McCully C, Tucker C, Balis FM (2008) The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Cancer Chemother Pharmacol 62:387-392